Abstract:OBJECTIVE:To explore the circadian blood pressure (BP) profile and its influencing factors in essential hypertensive patients after treatment. METHODS:Cross-sectional surveillance was carried out in essential hypertensive subjects after treatment whose clinic blood pressure had been under control as 140/90 mm Hg (1 mm Hg = 0.133 kPa) for at least one month. All patients underwent a twenty-four-hour ambulatory blood pressure monitoring device (spacelabs 90207). The nocturnal fall of blood pressure (BP) was calculated from (daytime mean BP-night-time mean BP)/daytime BP, while 'daytime' values were recorded between 6 h and 22 h and 'night-time' values between 22 h and 6 h. Non-dippers were defined as those whose nocturnal decrease in mean systolic BP and/or mean diastolic BP was < 10% of the daytime BP. Binary logistic regression analysis was used to evaluate the correlation between circadian blood pressure profile and factors as gender, age, height, body mass index (BMI), family history of premature cardiovascular disease, women under age 65 or men under age 55, smoking habits, grade of hypertension, and strategy of antihypertensive drugs. RESULTS:208 treated essential hypertensive patients were enrolled in the study. 79 individuals were dippers and 129 were non-dippers. Data from logistic regression analysis showed that four factors as age, premature family history of cardiovascular disease, overweight or obesity, and strategy of antihypertensive drugs were significantly influencing the circadian blood pressure profile in treated hypertensive patients. The incidence of non-dippers in patients of 70 years of age or older and those between 60 and 69 were 3.3 and 2.3 times of those with less than 60 (P = 0.009 and 0.031, respectively). The prevalence of non-dippers in patients with a premature family history of cardiovascular disease was 3.7 times greater than those in subjects without a premature history of cardiovascular disease (P = 0.029). Similarly, the incidence of non-dippers in patients of overweight (24 = BMI < 28) and obesity (BMI >/= 28) were 3.0 and 4.8 times of those in subjects of normal weight (P = 0.003 and 0.009, respectively). Compared with patients treated with long-acting calcium channel blockers (CCBs), patients treated with angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) alone had less prevalence of nondippers (OR = 0.139, P = 0.010). Patients treated with joint antihypertensive scheme including ACE inhibitors or ARBs(but not including diuretics) had the tendency of lower incidence of abnormal circadian blood pressure rhythm (OR = 0.453, P = 0.118). Patients treated with joint antihypertensive scheme including diuretics (not including ACE inhibitors or ARBs) and with joint antihypertensive strategy including diuretics and ACE inhibitors or ARBs had lower incidence of nondippers (OR = 0.378 and 0.273, respectively; P = 0.030 and 0.011, respectively). CONCLUSIONS:Approximately 2/3 treated essential hypertensive patients had a non-dipper blood pressure profile. Age, premature family history of cardiovascular disease, overweight/obesity, and antihypertensive drugs strategy were correlated with circadian blood pressure profile. Compared with long-acting CCBs, diuretics, ACE inhibitors or ARBs might be helpful in keeping the circadian blood pressure rhythm at normal range.

Chronobiology of Natriuretic Peptides and Blood Pressure in Lean and Obese Individuals

Abstract 17325: Obesity, Blood Pressure, and Diurnal Variation in Natriuretic Peptides: A Clinical Trial

Correlation Between B Type Natriuretic Peptide And Metabolic Risk Factors

Relationships of Blood Pressure Circadian Rhythm and Brain Natriuretic Peptide with Left Ventricular Hypertrophy in the Patients with Primary Hypertension

Clinical significance and changes of plasma brain natriuretic peptide level in patients with chronic obstructive pul monary disease under different conditions

Natriuretic Peptide Normative Levels and Deficiency

Impact of obesity on echocardiographic parameters and N-terminal pro-brain natriuretic peptide levels in patients with heart failure with mid-range ejection fraction: unanswered questions

Profile on Circadian Blood Pressure and the Influencing Factors in Essential Hypertensive Patients after Treatment

EXERCISE AS MEDICINE; CHRONOTHERAPY IN HYPERTENSION MANAGEMENT

Associations of ambulatory blood pressure measurements with high-sensitivity troponin and natriuretic peptide levels in SPRINT

Oscillations of Hemodynamic Parameters Induced by Negative Pressure Breathing in Healthy Humans

Relationship Between N-Terminal Pro-B-Type Natriuretic Peptide Levels and Metabolic Syndrome

B-Type Natriuretic Peptide—A Paradox in the Diagnosis of Acute Heart Failure with Preserved Ejection Fraction in Obese Patients

Blunted increase in plasma BNP during acute coronary syndrome attacks in obese patients

P065 NOCUTRNAL BLOOD PRESSURE AND ITS CLINICAL CLASSIFICATION ARE GREATLY AFFECTED BY HYDROSTATIC PRESSURE AND POSTURAL CHANGES BETWEEN MEASUREMENTS

Systematic Brain Natriuretic Peptide Measurement for Cardiac Screening in Patients with Severe Obesity: The OLECOEUR Study

PS-C02-9: ASSOCIATIONS OF SHORT-TERM BLOOD PRESSURE VARIABILITY WITH ELECTROCARDIOGRAM PARAMETERS IN OBESITY-RELATED HYPERTENSION

Atrial natriuretic peptide and leptin interactions in healthy men

Clinical Research about the Relation Between B-type Natriuretic Peptide Level and the Dry Weight of Maintenance Hemodialysis Patients

Body Composition Measures and N-terminal pro-B-type Natriuretic Peptide (NT-pro-BNP) in US Adults

Pathophysiology of the Nondipping Blood Pressure Pattern